{"type":"trials","record":{"id":41941,"source_id":"clinicaltrials-gov","external_id":"NCT04832724","title":"RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)","brief_summary":"RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (nAMD) also referred to as Wet AMD. Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. The purpose of this phase 2, open label study is to evaluate whether different doses of RGX-314 from two different formulations (clinical versus eventual commercial formulation) perform the same in humans when delivered by subretinal administration","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"AbbVie","enrollment":60,"countries":["United States"],"start_date":"2021-02-22","completion_date":"2024-03-18","last_update_date":"2024-09-05","source_url":"https://clinicaltrials.gov/study/NCT04832724","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 89 Years","comparator":null,"organization":"AbbVie","interventions":["RGX-314"],"registry_source":"ClinicalTrials.gov","outcome_measures":["RGX-314 target protein concentration in aqueous humor — At Week 24","Incidence and severity of ocular Adverse Events (AEs) and overall AEs — Through Week 48","Changes in Best Corrected Visual Acuity (BCVA) — At Week 24 and 48","Changes in Central Retinal Thickness (CRT) — At Week 24 and 48","Mean Supplemental anti-VEGF injection annualized rate through week 24 and week 48 — Through Week 24 and week 48"],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Wet Macular Degeneration","Wet Age-related Macular Degeneration","RGX-314"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04832724","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-02-22 to 2024-03-18","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 89 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.896Z","intervention":["RGX-314"],"participants":60,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["RGX-314 target protein concentration in aqueous humor — At Week 24","Incidence and severity of ocular Adverse Events (AEs) and overall AEs — Through Week 48","Changes in Best Corrected Visual Acuity (BCVA) — At Week 24 and 48","Changes in Central Retinal Thickness (CRT) — At Week 24 and 48","Mean Supplemental anti-VEGF injection annualized rate through week 24 and week 48 — Through Week 24 and week 48"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41941","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}